Novel four-disulfide insulin analog with high aggregation stability and potency

Area of Science:

• Biochemistry
• Protein Engineering
• Endocrinology

Background:

• Insulin therapy, established for nearly a century, faces challenges in therapeutic efficacy and patient convenience.
• A major limitation is insulin's instability, requiring refrigeration to prevent inactivation via aggregation and fibrillation.
• Improving insulin's stability could significantly enhance its therapeutic application and ease of use.

Purpose of the Study:

• To engineer a novel insulin analog with enhanced stability against aggregation and fibrillation.
• To investigate the impact of an additional disulfide bond on insulin's structure, activity, and stability.
• To develop a more convenient and effective insulin formulation for therapeutic use.

Main Methods:

• Introduction of a fourth disulfide bond between the insulin A and B chains (A22-B22 linkage).
• Assessment of insulin analog activity through in vitro and in vivo potency studies.
• Determination of the tertiary structure of the four-disulfide analog using X-ray crystallography.
• Evaluation of aggregation stability compared to native insulin.

Main Results:

• An insulin analog with an A22-B22 disulfide bond retained significant insulin activity.
• X-ray crystallography confirmed that the A22-B22 analog maintains native insulin tertiary structure.
• The four-disulfide analog exhibited comparable in vivo potency to native insulin in mouse models.
• The novel analog demonstrated markedly improved stability against aggregation and fibrillation.

Conclusions:

• A novel four-disulfide insulin analog (A22-B22) has been successfully engineered.
• This analog maintains structural integrity and therapeutic potency while exhibiting superior aggregation stability.
• The findings suggest a promising new direction for developing more stable and convenient insulin formulations.